Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Primary Immune Thrombocytopenia (ITP)

NCT01443351 is registered in ClinicalTrials.gov with Zealand University Hospital as lead sponsor.

NCT NCT01443351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01443351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Primary Immune Thrombocytopenia (ITP)
Lead sponsor
Zealand University Hospital
Phase
Observational
Overall status
Withdrawn
Start date
March 31, 2015
Completion date
August 31, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura